Payment overview · 2025
General Payments
$34.31
2 reported records · 2 companies
Healthcare provider profile · identity verified
Colleen Collins, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MONTROSS, VA · NPI 1427036623
Verified facts
What the public records show
CMS Open Payments records show Colleen Collins, NP received $34.31 in general payments during 2025 across 2 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 54.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.46 | 45.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $18.85 | 1 |
| Food and Beverage | $15.46 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
64 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 87 |
| Lisinopril | Lisinopril | 191 | 53 |
| Furosemide | Furosemide | 181 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 39 |
| Omeprazole | Omeprazole | 162 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 53 |
| Potassium Chloride | Potassium Chloride | 138 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 43 |
| Jardiance | Empagliflozin | 129 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 35 |
| Glipizide Er | Glipizide | 120 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 29 |
| Ezetimibe | Ezetimibe | 107 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 31 |
| Trazodone Hcl | Trazodone Hcl | 97 | 23 |
| Carvedilol | Carvedilol | 95 | 23 |
| Losartan Potassium | Losartan Potassium | 95 | 22 |
| Trulicity | Dulaglutide | 90 | 17 |
| Famotidine | Famotidine | 88 | 21 |
| Bupropion Xl | Bupropion Hcl | 82 | 17 |
| Gabapentin | Gabapentin | 82 | 26 |
| Meloxicam | Meloxicam | 81 | 24 |
| Metformin Hcl Er | Metformin Hcl | 79 | 26 |
| Montelukast Sodium | Montelukast Sodium | 74 | 17 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 69 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 22 |
| Sertraline Hcl | Sertraline Hcl | 65 | 14 |
| Buspirone Hcl | Buspirone Hcl | 64 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 64 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 16 |
| Allopurinol | Allopurinol | 61 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 14 |
| Metformin Hcl | Metformin Hcl | 50 | 16 |
| Simvastatin | Simvastatin | 49 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Prednisone | Prednisone | 30 | 12 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Breyna | Budesonide/Formoterol Fumarate | 24 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Xl | Glipizide | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.31 · 2 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, BEXSERO, JARDIANCE, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error